CollaneX Therapeutics: working on a breakthrough in the fight against fibrosis
Fibrosis is the excessive formation of connective tissue in an organ or tissue; it is known from scars, but it can also occur in the liver as a result of obesity. An unhealthy lifestyle causes liver fibrosis to increase to such an extent that the disease almost begins to take on epidemic proportions, and no medicine is yet available. TNO has built up unique knowledge over the past decade that it wants to co-develop further with market parties into an effective medicine. This is currently being done by the newly founded CollaneX Therapeutics, a spin-off company of TNO. This biotech company will develop medicines against fibrosis, initially during the first phase of development independently, later in collaboration with pharmaceutical companies.
Working on a breakthrough in the fight against fibrosis
Fibrosis is the excessive formation of connective tissue in an organ or tissue; it is known from scars, but it can also occur in the liver as a result of obesity. An unhealthy lifestyle causes liver fibrosis to increase to such an extent that the disease almost begins to take on epidemic proportions, and no medicine is yet available. TNO has built up unique knowledge over the past decade that it wants to co-develop further with market parties into an effective medicine.
This is currently being done by the newly founded CollaneX Therapeutics, a spin-off company of TNO. This biotech company will develop medicines against fibrosis, initially during the first phase of development independently, later in collaboration with pharmaceutical companies.
Number of patients growing
Efforts to develop anti-fibrosis medicines are happening worldwide. Fibrosis can occur in many organs, such as the heart, lungs, liver and kidneys, and the number of patients with liver fibrosis is rising sharply. In the US alone 130 million people are affected by obesity, which in many cases leads to liver disorders and consequently an increase in the number of liver transplants as a result of fibrosis.
Why from TNO?
As a TNO spin-off, CollaneX has unique knowledge of both the disease and the pharmaceutical market. The scientists forming the company have developed numerous models that provide insight into the mechanisms of the disease as well as identified a unique target that helps to develop a medicine with potentially few side effects. The unique combination of knowledge of mechanisms, models and the market has convinced CollaneX that it can make a breakthrough in the fight against fibrosis.
Contact us
-
Susanna Rademaekers
Functie:Tech Transfer Support-
Standplaats:Den Haag - New Babylon
-
Telefoon:+31 6 15 93 16 57
-
Email:Email Susanna
-
LinkedIn:Susanna on LinkedIn
-
Get inspired
CO2 reduction and green carbon in industry
This is the time to reduce CO2 emissions and create new opportunities for a sustainable, circular industry. TNO experts present three innovative technologies that convert carbon and CO2 into sustainable products such as plastics, fuels and food.
From #plasticfree to future-proof plastics
On June 5th, we co-hosted a webinar with Fraunhofer UMSICHT, 'From plastic-free to future-proof plastics', where we shared insights from our whitepaper 'How a future-proof, circular and sustainable plastics economy should look like'.
Personalised Health: From science to market
Are you interested in developing personalised health in order to contribute to a healthier society? Get inspired by the experience of companies that already innovate with us. Watch this interactive webinar for the latest insights in personalised health: from science to market.
Switch to the hybrid energy system
How will our future electricity grid remain stable and affordable? Watch the webinar from 1 February 2023 and get an insight into the technological and societal solutions for our future energy system.
Offshore wind under pressure
Offshore wind energy is growing enormously, but this growth comes with challenges. To maximize the value of large volumes of wind energy in the future energy system, we need to ensure feasible business cases for developers.